Clintec expands UK headquarters and is presented with Queens Award for Enterprise – International Trade
Company's additional 4327-sq ft floor at Clintec’s Glasgow-based headquarters forms a fully dedicated centre of excellence for clinical research and quality assurance capabilities.
Clintec has been presented with the Queens Award for Enterprise 2017, in the category of International Trade - by Lord Provost, Eva Bolander in her capacity as Lord Lieutenant. The award ceremony coincides with the company's continued expansion – with the official opening of an additional 4327-sq ft floor at Clintec’s Glasgow-based headquarters, with the additional space forming a fully dedicated centre of excellence for clinical research and quality assurance capabilities.
The Queens Award, the highest business accolade that can be granted to any business operating within the UK, recognises outstanding corporate achievement and more than 20 years of consistent business success.
Dr Rabinder Buttar, Founder and CEO of Clintec, said: “We are honoured to have received the Queens Award for Enterprise for the second time – through which we celebrate 20 years of global success in clinical research. Furthermore, we are delighted to mark today with the expansion of our clinical operational capabilities and HQ office space for the next stage of company growth.”
She added: “Clintec’s high quality performance and service offering that we have consistently delivered to our customers over the past two decades, is well acknowledged. This includes our global footprint, with local expertise, flexibility, agility and high level of service with senior management closely involved in the innovative clinical development programmes we expertly deliver.”
The Lord Provost said: “Clintec International Ltd is a phenomenal success story. It therefore gave me immense pleasure, as Lord Lieutenant, to present its founder and Chief Executive, Dr Rabinder Buttar, with the Queen’s Award for International Trade. This dynamic Glasgow based company, which I was delighted to be given a tour of, has excelled itself in its short lifetime contributing to the city’s diverse business life. This represents its second Queen’s Award. It already has a highly deserved Queen’s Award for Enterprise.”
At the visit of the Lord Provost to Clintec’s HQ, Sophie Totten, Clintec’s first Master’s Graduate in International Clinical Research & Technology, was recognised for the Master’s Degree developed by Clintec jointly with Edinburgh Napier University. Sophie trained as a CRA at Clintec and has been part of the team that has excelled in delivering clinical monitoring services to a Clintec client - one of the top pharmaceutical companies in the world.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance